Skip to main content
Top

12-03-2025 | Hepatocellular Carcinoma | Original Article

Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma

Authors: Yuki Tsuji, Tadashi Namisaki, Hiroaki Takaya, Naoki Nishimura, Ryuichi Noguchi, Shohei Asada, Akihiko Shibamoto, Takahiro Kubo, Satoshi Iwai, Fumimasa Tomooka, Aritoshi Koizumi, Takuya Matsuda, Misako Tanaka, Nobuyuki Yorioka, Takashi Inoue, Yukihisa Fujinaga, Norihisa Nishimura, Koh Kitagawa, Shinya Sato, Kosuke Kaji, Kiyoshi Asada, Akira Mitoro, Hitoshi Yoshiji

Published in: Digestive Diseases and Sciences

Login to get access

Abstract

Aim

The incidence of intrahepatic distant recurrence (IDR) of hepatocellular carcinoma (HCC) still remains high after radiofrequency ablation (RFA). However, serum alpha-fetoprotein (AFP) has insufficient screening power. This study aimed to identify risk factors for IDR in patients with post-RFA HCC.

Method

A total of 112 patients with early-stage HCC who underwent RFA were divided into the IDR (n = 51) and non-IDR groups (n = 61). Serum samples were analyzed within 2 months after RFA.

Results

The mean follow-up duration was 30.1 months. The recurrence-free survival rates at 1, 3, and 5 years were 20.8%, 42.4%, and 54.2%, respectively. The 1- and 5-year overall survival rates were 97.3% and 87.3%, respectively. Univariate and multivariate analyses revealed that the neutrophil-to-lymphocyte ratio [NLR, hazard ratio (HR) 2.40; 95% confidence interval (CI) 1.44–3.99] and lens culinaris agglutinin a-reactive fraction of alpha-fetoprotein (AFP-L3, (HR 1.02; 95% CI 1.01–1.04) were independently associated with post-RFA IDR. The cumulative recurrence rates at 5 years in the high NLR (≥ 2.24) and high AFP-L3 (≥ 0.2 ng/mL) groups were significantly higher than those in the low NLR (< 2.24) and low AFP-L3 (< 0.2 ng/mL) groups, respectively. The predictive accuracies of NLR, AFP-L3, and a composite index based on AFP-L3, and NLR for IDR were 66.2% (37.3% sensitivity, 95.1% specificity), 64.3% (47.1% sensitivity, 80.3% specificity), and 75.6% (68.6% sensitivity, 75.4% specificity), respectively.

Conclusion

The combined model had significantly better prediction performance than either NLR or AFP-L3 alone. The NLR combined with an absolute AFP-L3 level is an effective marker for IDR in patients with post-RFA HCC.
Literature
1.
go back to reference Matsumoto K, Wu Y, Kitazawa T, Fujita S, Seto K, Hasegawa T. Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections. PLoS ONE. 2018;13:e0199188.CrossRefPubMedPubMedCentral Matsumoto K, Wu Y, Kitazawa T, Fujita S, Seto K, Hasegawa T. Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections. PLoS ONE. 2018;13:e0199188.CrossRefPubMedPubMedCentral
2.
go back to reference Kim YS, Lim HK, Rhim H et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89–97.CrossRefPubMed Kim YS, Lim HK, Rhim H et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89–97.CrossRefPubMed
3.
go back to reference Lee DH, Lee JM, Lee JY et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014;270:900–909.CrossRefPubMed Lee DH, Lee JM, Lee JY et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014;270:900–909.CrossRefPubMed
5.
go back to reference Kudo M, Kawamura Y, Hasegawa K et al. Management of hepatocellular carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10:181–223.CrossRefPubMedPubMedCentral Kudo M, Kawamura Y, Hasegawa K et al. Management of hepatocellular carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10:181–223.CrossRefPubMedPubMedCentral
6.
go back to reference Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–1570.CrossRefPubMed Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–1570.CrossRefPubMed
7.
8.
go back to reference Mandaliya H, Jones M, Oldmeadow C, Nordman II. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8:886–894.CrossRefPubMedPubMedCentral Mandaliya H, Jones M, Oldmeadow C, Nordman II. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8:886–894.CrossRefPubMedPubMedCentral
9.
go back to reference Prabawa IPY, Bhargah A, Liwang F et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pac J Cancer Prev. 2019;20:863–868.CrossRefPubMedPubMedCentral Prabawa IPY, Bhargah A, Liwang F et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pac J Cancer Prev. 2019;20:863–868.CrossRefPubMedPubMedCentral
10.
go back to reference Chen X, Mohammed AF, Li C. Assessment of the clinical value of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma. Clin Appl Thromb Hemost. 2024;30:10760296231221536.CrossRefPubMedPubMedCentral Chen X, Mohammed AF, Li C. Assessment of the clinical value of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma. Clin Appl Thromb Hemost. 2024;30:10760296231221536.CrossRefPubMedPubMedCentral
11.
go back to reference Chen Y, Yang Y, Zhang XY et al. Nomogram based on neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio to predict recurrence in patients with hepatocellular carcinoma after radiofrequency ablation. Cardiovasc Interv Radiol. 2021;44:1551–1560.CrossRef Chen Y, Yang Y, Zhang XY et al. Nomogram based on neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio to predict recurrence in patients with hepatocellular carcinoma after radiofrequency ablation. Cardiovasc Interv Radiol. 2021;44:1551–1560.CrossRef
12.
go back to reference Hasegawa K, Takemura N, Yamashita T et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383–390.CrossRefPubMed Hasegawa K, Takemura N, Yamashita T et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383–390.CrossRefPubMed
13.
go back to reference Abraldes JG, Bureau C, Stefanescu H et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology. 2016;64:2173–2184.CrossRefPubMed Abraldes JG, Bureau C, Stefanescu H et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology. 2016;64:2173–2184.CrossRefPubMed
14.
15.
go back to reference Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: a meta-analysis. Medicine (Baltim) 2021;100:e27673.CrossRef Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: a meta-analysis. Medicine (Baltim) 2021;100:e27673.CrossRef
16.
go back to reference Olbrich A, Niemeyer J, Seiffert H et al. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2024;150:81.CrossRefPubMedPubMedCentral Olbrich A, Niemeyer J, Seiffert H et al. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2024;150:81.CrossRefPubMedPubMedCentral
17.
go back to reference Best J, Bilgi H, Heider D et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016;54:1296–1305.CrossRefPubMed Best J, Bilgi H, Heider D et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016;54:1296–1305.CrossRefPubMed
18.
go back to reference Chen H, Zhang Y, Li S et al. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res. 2018;10:1947–1958.CrossRefPubMedPubMedCentral Chen H, Zhang Y, Li S et al. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res. 2018;10:1947–1958.CrossRefPubMedPubMedCentral
19.
go back to reference Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology. 2019;69:1983–1994.CrossRefPubMed Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology. 2019;69:1983–1994.CrossRefPubMed
20.
go back to reference Li B, Li B, Guo T et al. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of alpha-fetoprotein, alpha-fetoprotein-L3, des-gamma-carboxy prothrombin, and Golgi protein 73. Oncotarget. 2017;8:80521–80530.CrossRefPubMedPubMedCentral Li B, Li B, Guo T et al. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of alpha-fetoprotein, alpha-fetoprotein-L3, des-gamma-carboxy prothrombin, and Golgi protein 73. Oncotarget. 2017;8:80521–80530.CrossRefPubMedPubMedCentral
21.
go back to reference Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110–118.CrossRefPubMed Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110–118.CrossRefPubMed
22.
go back to reference Moriya S, Morimoto M, Numata K et al. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma. Anticancer Res. 2013;33:997–1001.PubMed Moriya S, Morimoto M, Numata K et al. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma. Anticancer Res. 2013;33:997–1001.PubMed
23.
go back to reference Chaiteerakij R, Zhang X, Addissie BD et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transplant. 2015;21:599–606.CrossRef Chaiteerakij R, Zhang X, Addissie BD et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transplant. 2015;21:599–606.CrossRef
24.
go back to reference Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R et al. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol. 2018;24:1321–1331.CrossRefPubMedPubMedCentral Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R et al. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol. 2018;24:1321–1331.CrossRefPubMedPubMedCentral
25.
go back to reference Yang Y, Cao Y. The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. 2022;86:251–261.CrossRefPubMed Yang Y, Cao Y. The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. 2022;86:251–261.CrossRefPubMed
26.
go back to reference Paskeh MDA, Entezari M, Mirzaei S et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15:83.CrossRefPubMedPubMedCentral Paskeh MDA, Entezari M, Mirzaei S et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15:83.CrossRefPubMedPubMedCentral
27.
go back to reference Chen K, Zhan MX, Hu BS et al. Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncol Lett. 2018;15:315–323.PubMed Chen K, Zhan MX, Hu BS et al. Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncol Lett. 2018;15:315–323.PubMed
28.
go back to reference Chu MO, Shen CH, Chang TS et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation. Sci Rep. 2018;8:16611.CrossRefPubMedPubMedCentral Chu MO, Shen CH, Chang TS et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation. Sci Rep. 2018;8:16611.CrossRefPubMedPubMedCentral
29.
go back to reference Kawka M, Dawidziuk A, Jiao LR, Gall TMH. Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review. Transl Gastroenterol Hepatol. 2022;7:41.CrossRefPubMedPubMedCentral Kawka M, Dawidziuk A, Jiao LR, Gall TMH. Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review. Transl Gastroenterol Hepatol. 2022;7:41.CrossRefPubMedPubMedCentral
Metadata
Title
Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma
Authors
Yuki Tsuji
Tadashi Namisaki
Hiroaki Takaya
Naoki Nishimura
Ryuichi Noguchi
Shohei Asada
Akihiko Shibamoto
Takahiro Kubo
Satoshi Iwai
Fumimasa Tomooka
Aritoshi Koizumi
Takuya Matsuda
Misako Tanaka
Nobuyuki Yorioka
Takashi Inoue
Yukihisa Fujinaga
Norihisa Nishimura
Koh Kitagawa
Shinya Sato
Kosuke Kaji
Kiyoshi Asada
Akira Mitoro
Hitoshi Yoshiji
Publication date
12-03-2025
Publisher
Springer US
Published in
Digestive Diseases and Sciences
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-025-08884-5

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video